Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label trial of continuous oral BIBW 2992 in relapsed or refractory solid tumours and recurrent glioblastoma
2008-006288-36Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in Nonhematologic neoplasms, glioblastoma (GBM), brain metastases, sponsored by Boehringer Ingelheim. Started Jun 2009; status: completed.
02
Drugs
afatinib
03
Conditions
Nonhematologic neoplasmsglioblastoma (GBM)brain metastases
Beyond the preview
Go deeper on 2008-006288-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006288-36.